Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

3719 - A prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with radiotherapy for non-small-cell lung cancer patients with bone metastasis


08 Oct 2016


Poster Display


Leiming Guo


Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383


L. Guo1, G.F. Ding2

Author affiliations

  • 1 Department Of Radiotherapy, Henan Provincial Anti-Cancer Hospital, 450000 - Zhengzhou/CN
  • 2 Department Of Radiotherapy, Henan Provincial Anti-Cancer Hospital, Zhengzhou/CN


Abstract 3719


To establish the safety profile and efficacy of epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs) concurrent with radiotherapy (RT) in patients with non–small-cell lung cancer (NSCLC) who have only bone oligometastases (1-3 lesions) progression after EGFR-TKIs therapy.


Between June 2012 and January 2015, 28 patients with Stage IV NSCLC were enrolled in this prospective study. They were treated with EGFR-TKIs (gefitinib 250mg or erlotinib 150 mg, oral daily), and concurrent with bone metastasis RT with curative intent when these patients had only bone oligometastases (1-3 lesions) progression. The RT plans were individually designed on the basis of tumor size and normal tissue volume constraints. The RT plans have two styles: 30Gy/10f. All patients were available for assessment of toxicity and efficacy. The primary endpoints were acute toxicity and overall survival. The secondary endpoints included median survival time and progression-free survival (PFS).


All patients completed the treatment protocol. Acute skin, hematologic, esophageal, gastrointestinal and systemic toxicities were mild. No serious adverse reaction was noted. With a median follow-up of 21.5 months, the local control rate of 92.8% was achieved for the bone metastases lesions. Median PFS, and median survival time were 16.2, and 21.5 months, respectively. The 1- and 2-year PFS rates were 69.8% and 26.2%, and 1-, 2-, and 3-year overall survival rates were 77.9%, 46.8%, and 23.4%, respectively.


For advanced NSCLC patients effectively treated with EGFR-TKIs, concurrent with individualized bone metastases lesions RT shows a favorable safety profile and promising outcome, therefore can serve as a therapeutic option for advanced NSCLC patients with only bone oligometastases progression.

Clinical trial identification

Legal entity responsible for the study

Henan Province Anti-cancer Hospital


Henan Province Anti-cancer Hospital


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings